Apr 23rd 2012 - Edison Investment Research today published a report on Deltex Medical (DEMG.L, LSE:DEMG, LON:DEMG) entitled "NHS Sales Up 40%". In summary, the report says:
The £1.5m raised by Deltex provides additional working capital given the 40% rise in NHS orders experienced in Q1. NHS hospitals are under significant NHS executive and financial pressure to adopt surgical fluid management by March 2013. This is likely to drive an acceleration in probe and monitor sales, particularly over autumn and winter. Q1 sales continued the 40% growth trend of late 2011. However, NHS trusts may hoard cash in H1 of their FY13 year. CardioQ has strong evidence of effectiveness and is the only NICE-recommended product.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »